Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Phathom Pharmaceuticals (PHAT) EBT Margin: 2022-2025

Historic EBT Margin for Phathom Pharmaceuticals (PHAT) over the last 4 years, with Sep 2025 value amounting to -60.53%.

  • Phathom Pharmaceuticals' EBT Margin rose 46276.00% to -60.53% in Q3 2025 from the same period last year, while for Sep 2025 it was -186.44%, marking a year-over-year increase of 110543.00%. This contributed to the annual value of -605.08% for FY2024, which is 2892630.00% up from last year.
  • Phathom Pharmaceuticals' EBT Margin amounted to -60.53% in Q3 2025, which was up 68.39% from -191.52% recorded in Q2 2025.
  • Phathom Pharmaceuticals' EBT Margin's 5-year high stood at 1,473.65% during Q1 2022, with a 5-year trough of -11,665.10% in Q4 2023.
  • Over the past 3 years, Phathom Pharmaceuticals' median EBT Margin value was -251.15% (recorded in 2024), while the average stood at -1,576.30%.
  • In the last 5 years, Phathom Pharmaceuticals' EBT Margin slumped by 1,223,745bps in 2023 and then surged by 1,141,396bps in 2024.
  • Quarterly analysis of 4 years shows Phathom Pharmaceuticals' EBT Margin stood at 572.35% in 2022, then plummeted by 1,223,745bps to -11,665.10% in 2023, then surged by 1,141,396bps to -251.15% in 2024, then spiked by 46,276bps to -60.53% in 2025.
  • Its EBT Margin stands at -60.53% for Q3 2025, versus -191.52% for Q2 2025 and -330.64% for Q1 2025.